FILING ANALYSIS · TUESDAY, NOVEMBER 10
PALISADE BIO, INC. PALI — 8-K: Results of Operations and Financial Condition
neutral
The company reported $113.6 million in cash and cash equivalents as of September 30, 2026, and announced the initiation of a global Phase 2b clinical trial for PALI-2108, with topline results expected in Q4 2027, but there is no quantified surprise in the filing to suggest a significant price move.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →